Physician profile
Darby Cole
NPI 1306838693
$2,772.16
in general payments reported to CMS, 2019-2025
27 companies · $141 in 2025
The $141 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $700 · 2020: $445 · 2021: $722 · 2022: $194 · 2023: $129 · 2024: $441 · 2025: $141.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $712.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $711.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $328.13 | 2019-2025 | |
| Novo Nordisk INC | $312.49 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Lilly USA, LLC | $290.16 | 2019-2024 | Mounjaro, Trulicity, Jardiance |
| Janssen Pharmaceuticals, INC | $266.45 | 2019-2025 | Spravato |
| Amgen INC. | $237.68 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $198.38 | 2019-2024 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $193.65 | 2019-2022 | |
| Amarin Pharma, INC. | $171.22 | 2019-2021 | |
| Pfizer INC. | $119.13 | 2020-2025 | |
| Gilead Sciences, INC. | $96.12 | 2024 | |
| Abbvie INC. | $93.71 | 2019-2024 | |
| Glaxosmithkline, LLC. | $91.67 | 2020-2025 | Shingrix, Arexvy |
| Sanofi-Aventis U.S. LLC | $57.26 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $55.70 | 2019-2024 | Xifaxan |
| Corcept Therapeutics | $35.77 | 2022 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $31.93 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $25.36 | 2021 | |
| Merck Sharp & Dohme LLC | $24.71 | 2019 | |
| Coopersurgical, INC. | $23.16 | 2022 | |
| Otsuka America Pharmaceutical, INC. | $21.14 | 2023 | Nuedexta |
| Xeris Pharmaceuticals, INC. | $17.95 | 2024 | Gvoke Hypopen |
| Shire North American Group INC | $17.50 | 2019 | |
| Dynavax Technologies Corporation | $16.70 | 2022 | |
| Biogen, INC. | $14.42 | 2025 | Skyclarys |
| Ardelyx, INC. | $13.13 | 2024 | Ibsrela |
| Organon LLC | $10.54 | 2021 | |
| Linus Health, INC. | $8.10 | 2024 | Core Cognitive Evaluation |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Darby Cole listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.